WCN26-6348 PROTECTIVE ROLE OF FINERENONE AGAINST PODOCYTE INJURY THROUGH MR–TRPC PATHWAY INHIBITION IN DIABETIC KIDNEY DISEASE

Read full text Summarise with VIRAT
Authors: Tsukasa Iwakura, Kengo Kidokoro, Rie Tatsugawa, Masanobu Takasu, Masahumi Wada, Kitao Hiroshi, Akira Hirano, Yoshihisa Wada, Hajime Nagasu, Sasaki, Naoki Kashihara
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Finerenone, a non-steroidal selective mineralocorticoid receptor antagonist (nsMRA), has demonstrated renoprotective effects in patients with chronic kidney disease (CKD) and type 2 diabetes, as shown in the FIDELIO-DKD study. However, the underlying physiological mechanism responsible for its albuminuria-reducing effect remains incompletely understood. Animal studies have reported that excessive activation of mineralocorticoid receptors (MRs) in glomerular cells contributes to the progression of diabetic kidney disease (DKD) and albuminuria, and is also associated with metabolic abnormalities such as hypertension, heart failure, and type 2 diabetes.

Fields of Study & Subjects

Chronic Kidney Disease and Diabetes Renal Diseases and Glomerulopathies Hormonal Regulation and Hypertension

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
105825–105825
Publication date
25 March 2026
Language
EN